Haematological malignancies: at the forefront of immunotherapeutic innovation.

Nat Rev Cancer
Authors
Keywords
Abstract

The recent successes of cancer immunotherapies have stimulated interest in the potential widespread application of these approaches; haematological malignancies have provided both initial proofs of concept and an informative testing ground for various immune-based therapeutics. The immune-cell origin of many of the blood malignancies provides a unique opportunity both to understand the mechanisms of cancer immune responsiveness and immune evasion, and to exploit these mechanisms for therapeutic purposes.

Year of Publication
2015
Journal
Nat Rev Cancer
Volume
15
Issue
4
Pages
201-15
Date Published
2015 Apr
ISSN
1474-1768
URL
DOI
10.1038/nrc3907
PubMed ID
25786696
PubMed Central ID
PMC4511812
Links
Grant list
1R01CA155010-02 / CA / NCI NIH HHS / United States
U54 HG003067 / HG / NHGRI NIH HHS / United States
R01 HL103532 / HL / NHLBI NIH HHS / United States
U54HG003067 / HG / NHGRI NIH HHS / United States
T32CA009172 / CA / NCI NIH HHS / United States
T32 CA009172 / CA / NCI NIH HHS / United States
R01 CA155010 / CA / NCI NIH HHS / United States
5R01HL103532-03 / HL / NHLBI NIH HHS / United States